BACKGROUND Febrile neutropenia is a major toxicity of myelosuppressive chemotherapy. It is a potentially fatal complication which leads to increase in morbidity, mortality and treatment costs. Myeloid growth factors (colony-stimulating factors - CSFs) can effectively reduce the incidence of severe neutropenia in patients treated with high-risk chemotherapy regimens in both curative and palliati...

BACKGROUND Neutropenia is a major adverse event often associated with chemotherapy administration. Neutropenia-related complications often lead to increased use of costly health care including inpatient and outpatient services. Monitoring and treatment of neutropenia thus place an economic burden on the health care system. OBJECTIVES To evaluate (a) costs and medical resource use for chemothe...

OBJECTIVE Elevated levels of a cell surface glycoprotein, soluble cluster of differentiation 14 (sCD14), have been observed in patients with sepsis. Only scarce data are available on sCD14 in hematological patients with chemotherapy-induced febrile neutropenia. The study aim was to investigate sCD14 as an early biomarker in febrile neutropenia after intensive chemotherapy to detect a rapidly de...

Background: Febrile neutropenia is still one of the most important complications of treatment in cancer patients. These patients become prone to infection and consequently higher mortality and morbidity. This study aimed to determine the accuracy of serum procalcitonin (PCT) level in the detection of infection in pediatric cancer patients complicated with febrile neutropenia. Materials and Met...

BACKGROUND Sometimes, in pediatric oncology, it is difficult to differentiate the relapse of primary tumor from other diagnoses such as post-ischemic lesions or fungal abscess, without performing an organ biopsy. In addition, patients frequently are not under clinical conditions to be biopsied, mainly due to febrile neutropenia. A growing number of studies has focused on the use of Positron emi...

Background: Febrile neutropenia is one of the most serious adverse events in patients with hematological malignancies and chemotherapy. The routine use of fluoroquinolone prophylaxis in patients with hematological malignancies is controversial. Therefore, we prospectively evaluated the efficacy and safety of prophylactic use of garenoxacin for febrile neutropenia. Patients and Methods: Consecut...

Breast cancer is the most common cancer in women worldwide. Doxorubicin-based chemotherapy is used to treat breast cancer patients; however, neutropenia is a common hematologic side effect and can be life-threatening. The ABCB1 and SLC22A16 genes encode proteins that are essential for doxorubicin transport. In this study, we explored the effect of 2 common polymorphisms in ABCB1 (rs10276036 C/T...

Review Questions: What are the prognostic indicators predictive of chemotherapy-induced febrile neutropenia outcomes (favourable and unfavourable) among adult cancer patients? Background: Febrile Neutropenia (FN) is a major complication for cancer patients undergoing chemotherapy.1 It is associated with significant morbidity and mortality. Standard patient care includes prolonged hospitalizatio...

We evaluated risk factors for neutropenic fever and febrile prolonged neutropenia during vincristine-including chemotherapy to treat HIV-related lymphoma to investigate whether protease inhibitor (PI) treatment is associated with infectious complications due to drug interactions with chemotherapeutic agents. We included all HIV patients who received chemotherapy including vincristine for lympho...

Febrile neutropenia is a relatively frequent event in cancer patients treated with chemotherapy. In the United States, an estimated 60,000 patients a year are hospitalized for febrile neutropenia and neutropenia related infections (Cagganio et al., 2005). Our single institution data in previous two studies have shown the frequency to be ranging from 10 to 12 per month (Lal et al., 2008; Shaikh ...